Newly Granted Patent Application improves Patient Compliance
- haraldkattnig5
- May 27
- 2 min read
Updated: Jun 5
San Francisco, May 27, 2025 - Recardio Inc., a late stage clinical stage life science company developing therapies for cardiovascular and other diseases, announced that the European Patent Office has granted the new patent with the potential of significantly improving administration of the company’s lead drug candidate Dutogliptin.
The European Patent Office (EPO) has granted to Recardio in May a new patent, published as EP 4 514 359 B1. The patent relates to a novel formulation process of the company’s lead drug candidate Dutogliptin and was developed by the company in the past years.
Compared to the current daily application mode, this new formulation will enable a once per week administration in the targeted therapeutic setting and beyond resulting in potential significant easy use and compliance benefits for the patients.
This newly granted patent is extending Recardio’s patent protection for Dutogliptin into 2045 and the company is already in the process of converting this patent globally into national patents applications in key markets.
About Recardio
Recardio Inc. is a late-stage clinical life science company focusing on therapies for cardiovascular and other diseases.
The company is located in San Francisco, California, having its operations in USA and Europe.
The company’s lead drug candidate, Dutogliptin, is a DPP-IV inhibitor that has demonstrated pre- and clinically significant effects in activating various chemokines like SDF-1, a protein that is critical for cardiac regeneration resulting in healing cardiac tissue after an injury.
After receiving FDA and EMA approval, Recardio is currently preparing its global pivotal Phase 3 clinical program in acute myocardial infarction for market authorization in major markets and will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases.
In addition, other development programs are in earlier clinical and preclinical stage.
For more information, visit: http://www.recardio.eu/ or contact pr@recardio.eu
